Lai Wang Sells 5,000 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Lai Wang sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $220.35, for a total value of $1,101,750.00. Following the completion of the transaction, the insider now directly owns 920,920 shares of the company’s stock, valued at $202,924,722. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

BeiGene Stock Performance

BGNE traded up $6.47 during trading on Tuesday, reaching $230.98. The company’s stock had a trading volume of 333,145 shares, compared to its average volume of 250,874. The company’s fifty day moving average price is $189.26 and its 200-day moving average price is $166.47. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $237.10. The company has a market capitalization of $22.38 billion, a price-to-earnings ratio of -29.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. The business had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The company’s revenue was up 56.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.64) EPS. On average, equities analysts forecast that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BeiGene

Several institutional investors and hedge funds have recently made changes to their positions in BGNE. Swedbank AB purchased a new position in shares of BeiGene during the 1st quarter worth approximately $2,596,000. AIA Group Ltd increased its stake in BeiGene by 38.9% in the first quarter. AIA Group Ltd now owns 18,497 shares of the company’s stock valued at $2,893,000 after purchasing an additional 5,181 shares during the last quarter. M&G Plc acquired a new stake in BeiGene in the 1st quarter worth about $29,649,000. Driehaus Capital Management LLC purchased a new stake in BeiGene in the 2nd quarter valued at about $1,168,000. Finally, Van ECK Associates Corp increased its stake in shares of BeiGene by 8.9% during the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after acquiring an additional 7,816 shares during the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BGNE shares. JMP Securities began coverage on shares of BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target on the stock. Citigroup boosted their target price on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. raised their price target on BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Finally, Bank of America cut their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $241.21.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.